Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe

Ene Ly Jõgeda, Kristi Huik, Merit Pauskar, Eveli Kallas, Tõnis Karki, Don Des Jarlais, Anneli Uusküla, Irja Lutsar, Radko Avi

Research output: Contribution to journalArticle

Abstract

We aimed to determine the rate of GBV-C viremia, seropositivity, and genotypes among people who inject drugs (PWID) and healthy volunteers in Estonia and to evaluate associations between GBV-C and sociodemographic factors, intravenous drug use, co-infections. The study included 345 Caucasian PWID and 118 healthy volunteers. The presence of GBV-C RNA (viremia) was determined by reverse transcriptase-nested PCR in 5′ long terminal repeat. PCR products were sequenced and genotyped by phylogenetic analysis. GBV-C seropositivity was determined by ELISA. One third of PWID (114/345) and 6% (7/118) of healthy volunteers (OR = 7.8, 95% CI = 3.5–20.5, P < 0.001) were GBV-C viremic. In PWID group, 79% of sequences belonged to subtype 2a, 19% to subtype 2b, and two remained unclassified. In healthy volunteers, six out of seven sequences belonged to subtype 2a and one to subtype 2b. We found HIV+ PWID to have two times increased odds of being GBV-C viremic compared to HIV− PWID (62% vs. 38%; OR = 2.13, 95% CI = 1.34–3.36, P = 0.001). In addition, odds of being GBV-C viremic decreased with increasing age (OR = 0.94, 95% CI = 0.90–0.98, P = 0.001). HIV positivity remained associated with GBV-C viremia in multivariate analysis after adjustment for age (OR = 2.23, 95% CI = 1.39–3.58, P = 0.001). GBV-C seropositivity was similar among PWID and healthy volunteers (2.3% vs. 1.7%, respectively; OR = 1.4, 95% CI =0.3–13.5, P = 1). In an Eastern European country we demonstrated that GBV-C viremia is common among PWID, but uncommon among healthy volunteers, and GBV-C seropositivity is infrequent among both groups. Similarly to other European countries and USA, GBV-C 2a is the most common genotype in Estonia. J. Med. Virol. 89:632–638, 2017.

Original languageEnglish (US)
Pages (from-to)632-638
Number of pages7
JournalJournal of Medical Virology
Volume89
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

GB virus C
Eastern Europe
HIV Infections
Genotype
Pharmaceutical Preparations
Healthy Volunteers
Viremia
Estonia
HIV
Polymerase Chain Reaction
Terminal Repeat Sequences
Reverse Transcriptase Polymerase Chain Reaction
Coinfection

Keywords

  • HGV
  • IDU
  • seropositivity
  • viremia

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe. / Jõgeda, Ene Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Avi, Radko.

In: Journal of Medical Virology, Vol. 89, No. 4, 01.04.2017, p. 632-638.

Research output: Contribution to journalArticle

Jõgeda, Ene Ly ; Huik, Kristi ; Pauskar, Merit ; Kallas, Eveli ; Karki, Tõnis ; Des Jarlais, Don ; Uusküla, Anneli ; Lutsar, Irja ; Avi, Radko. / Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe. In: Journal of Medical Virology. 2017 ; Vol. 89, No. 4. pp. 632-638.
@article{3d0a985d17f14b76b1fffe33b96e2311,
title = "Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe",
abstract = "We aimed to determine the rate of GBV-C viremia, seropositivity, and genotypes among people who inject drugs (PWID) and healthy volunteers in Estonia and to evaluate associations between GBV-C and sociodemographic factors, intravenous drug use, co-infections. The study included 345 Caucasian PWID and 118 healthy volunteers. The presence of GBV-C RNA (viremia) was determined by reverse transcriptase-nested PCR in 5′ long terminal repeat. PCR products were sequenced and genotyped by phylogenetic analysis. GBV-C seropositivity was determined by ELISA. One third of PWID (114/345) and 6{\%} (7/118) of healthy volunteers (OR = 7.8, 95{\%} CI = 3.5–20.5, P < 0.001) were GBV-C viremic. In PWID group, 79{\%} of sequences belonged to subtype 2a, 19{\%} to subtype 2b, and two remained unclassified. In healthy volunteers, six out of seven sequences belonged to subtype 2a and one to subtype 2b. We found HIV+ PWID to have two times increased odds of being GBV-C viremic compared to HIV− PWID (62{\%} vs. 38{\%}; OR = 2.13, 95{\%} CI = 1.34–3.36, P = 0.001). In addition, odds of being GBV-C viremic decreased with increasing age (OR = 0.94, 95{\%} CI = 0.90–0.98, P = 0.001). HIV positivity remained associated with GBV-C viremia in multivariate analysis after adjustment for age (OR = 2.23, 95{\%} CI = 1.39–3.58, P = 0.001). GBV-C seropositivity was similar among PWID and healthy volunteers (2.3{\%} vs. 1.7{\%}, respectively; OR = 1.4, 95{\%} CI =0.3–13.5, P = 1). In an Eastern European country we demonstrated that GBV-C viremia is common among PWID, but uncommon among healthy volunteers, and GBV-C seropositivity is infrequent among both groups. Similarly to other European countries and USA, GBV-C 2a is the most common genotype in Estonia. J. Med. Virol. 89:632–638, 2017.",
keywords = "HGV, IDU, seropositivity, viremia",
author = "J{\~o}geda, {Ene Ly} and Kristi Huik and Merit Pauskar and Eveli Kallas and T{\~o}nis Karki and {Des Jarlais}, Don and Anneli Uusk{\"u}la and Irja Lutsar and Radko Avi",
year = "2017",
month = "4",
day = "1",
doi = "10.1002/jmv.24683",
language = "English (US)",
volume = "89",
pages = "632--638",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe

AU - Jõgeda, Ene Ly

AU - Huik, Kristi

AU - Pauskar, Merit

AU - Kallas, Eveli

AU - Karki, Tõnis

AU - Des Jarlais, Don

AU - Uusküla, Anneli

AU - Lutsar, Irja

AU - Avi, Radko

PY - 2017/4/1

Y1 - 2017/4/1

N2 - We aimed to determine the rate of GBV-C viremia, seropositivity, and genotypes among people who inject drugs (PWID) and healthy volunteers in Estonia and to evaluate associations between GBV-C and sociodemographic factors, intravenous drug use, co-infections. The study included 345 Caucasian PWID and 118 healthy volunteers. The presence of GBV-C RNA (viremia) was determined by reverse transcriptase-nested PCR in 5′ long terminal repeat. PCR products were sequenced and genotyped by phylogenetic analysis. GBV-C seropositivity was determined by ELISA. One third of PWID (114/345) and 6% (7/118) of healthy volunteers (OR = 7.8, 95% CI = 3.5–20.5, P < 0.001) were GBV-C viremic. In PWID group, 79% of sequences belonged to subtype 2a, 19% to subtype 2b, and two remained unclassified. In healthy volunteers, six out of seven sequences belonged to subtype 2a and one to subtype 2b. We found HIV+ PWID to have two times increased odds of being GBV-C viremic compared to HIV− PWID (62% vs. 38%; OR = 2.13, 95% CI = 1.34–3.36, P = 0.001). In addition, odds of being GBV-C viremic decreased with increasing age (OR = 0.94, 95% CI = 0.90–0.98, P = 0.001). HIV positivity remained associated with GBV-C viremia in multivariate analysis after adjustment for age (OR = 2.23, 95% CI = 1.39–3.58, P = 0.001). GBV-C seropositivity was similar among PWID and healthy volunteers (2.3% vs. 1.7%, respectively; OR = 1.4, 95% CI =0.3–13.5, P = 1). In an Eastern European country we demonstrated that GBV-C viremia is common among PWID, but uncommon among healthy volunteers, and GBV-C seropositivity is infrequent among both groups. Similarly to other European countries and USA, GBV-C 2a is the most common genotype in Estonia. J. Med. Virol. 89:632–638, 2017.

AB - We aimed to determine the rate of GBV-C viremia, seropositivity, and genotypes among people who inject drugs (PWID) and healthy volunteers in Estonia and to evaluate associations between GBV-C and sociodemographic factors, intravenous drug use, co-infections. The study included 345 Caucasian PWID and 118 healthy volunteers. The presence of GBV-C RNA (viremia) was determined by reverse transcriptase-nested PCR in 5′ long terminal repeat. PCR products were sequenced and genotyped by phylogenetic analysis. GBV-C seropositivity was determined by ELISA. One third of PWID (114/345) and 6% (7/118) of healthy volunteers (OR = 7.8, 95% CI = 3.5–20.5, P < 0.001) were GBV-C viremic. In PWID group, 79% of sequences belonged to subtype 2a, 19% to subtype 2b, and two remained unclassified. In healthy volunteers, six out of seven sequences belonged to subtype 2a and one to subtype 2b. We found HIV+ PWID to have two times increased odds of being GBV-C viremic compared to HIV− PWID (62% vs. 38%; OR = 2.13, 95% CI = 1.34–3.36, P = 0.001). In addition, odds of being GBV-C viremic decreased with increasing age (OR = 0.94, 95% CI = 0.90–0.98, P = 0.001). HIV positivity remained associated with GBV-C viremia in multivariate analysis after adjustment for age (OR = 2.23, 95% CI = 1.39–3.58, P = 0.001). GBV-C seropositivity was similar among PWID and healthy volunteers (2.3% vs. 1.7%, respectively; OR = 1.4, 95% CI =0.3–13.5, P = 1). In an Eastern European country we demonstrated that GBV-C viremia is common among PWID, but uncommon among healthy volunteers, and GBV-C seropositivity is infrequent among both groups. Similarly to other European countries and USA, GBV-C 2a is the most common genotype in Estonia. J. Med. Virol. 89:632–638, 2017.

KW - HGV

KW - IDU

KW - seropositivity

KW - viremia

UR - http://www.scopus.com/inward/record.url?scp=84987905645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987905645&partnerID=8YFLogxK

U2 - 10.1002/jmv.24683

DO - 10.1002/jmv.24683

M3 - Article

VL - 89

SP - 632

EP - 638

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 4

ER -